COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
DN Deutsche Nachhaltigkeit Expands Executive Board: Sustainability Expert Dr. Andreas Rickert Appointed Chief Impact Officer
DN Deutsche Nachhaltigkeit expands Executive Board by appointing Dr. Andreas Rickert as Chief Impact Officer, enhancing the company's positioning as an impact investor. Dr. Rickert brings extensive expertise in sustainability, social impact, and private equity -
-
COMMUNIQUÉ DE PRESSE
Qanatpharma, Zuse Institute Berlin, Enamine, and Proteros biostructures Announce Generative-AI Driven Lead Discovery Collaboration
Qanatpharma, Zuse Institute Berlin, Enamine, and Proteros biostructures collaborate on Generative-AI Driven Lead Discovery for treating brain hemorrhage complications. Research focuses on delaying cerebral ischemia. Program combines AI, drug design, compound synthesis, and hit validation -
COMMUNIQUÉ DE PRESSE
Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Quebec and Two Federal Programs
Bausch Health Canada Inc. launches CABTREO triple-combination gel for acne vulgaris, now accessible through public drug plans in Ontario, Nova Scotia, and federal government programs -
COMMUNIQUÉ DE PRESSE
Le traitement pour l’acné vulgaire de Bausch Health, Canada Inc., (Pr)CABTREO(MC) (gel de phosphate de clindamycine, d’adapalène et de peroxyde de benzoyle), est maintenant couvert par les régimes publics de l’Ontario, de la Nouvelle Écosse et p
Bausch Health Canada lance CABTREO, un nouveau gel topique \/ acné vulgaire. Disponible via assurance-médicaments en Ontario, Nouvelle-Écosse et pour les Premières Nations. Traitement triple combinaison approuvé par Santé Canada -
-
-
-
